GLP-1 + Cagrilintide
Key Potential Benefits of Cagrilintide + Semaglutide (CagriSema)
Superior Weight Loss (Potentially Among the Strongest Non-Surgical Options)
In REDEFINE 1 (adults with overweight/obesity without diabetes): Mean body weight reduction of 20.4% (treatment policy) to 22.7% (if all adhered to treatment) at 68 weeks, with continued loss and no clear plateau in many participants; 40–53% achieved ≥20% weight loss and up to 34.7% achieved ≥25%.
In REDEFINE 2 (adults with overweight/obesity and type 2 diabetes): Mean weight loss of 13.7–15.7% at 68 weeks.
In REIMAGINE 2 (type 2 diabetes): 14.2% weight loss vs 10.2% with semaglutide 2.4 mg alone at 68 weeks.
Outperforms monotherapy: Superior to semaglutide alone (by ~5.5%) and cagrilintide alone (by ~8.9%) in head-to-head comparisons, approaching or rivaling outcomes seen with more invasive interventions in select data.
Enhanced Satiety, Appetite Control, and Reduced Food Intake
Cagrilintide activates amylin receptors in the brainstem and hypothalamus to promote profound feelings of fullness, reduce hunger signals, and blunt the rewarding aspects of food.
Semaglutide provides strong GLP-1-mediated appetite suppression, delayed gastric emptying, and reduced cravings.
Together: Complementary multi-pathway reinforcement (GLP-1 + amylin) leads to more robust and sustained satiety, improved adherence, and fewer compensatory hunger episodes compared to either agent alone.
Improved Glycemic Control and Type 2 Diabetes Management
Significant HbA1c reductions: Up to 1.91 percentage points in REIMAGINE 2 (superior to 1.76 points with semaglutide alone); ~1.8–2.2 points in earlier trials.
High rates of target achievement: 73.5% reaching HbA1c ≤6.5% and up to 89% reaching <7.0% in some studies.
Enhances insulin sensitivity, suppresses postprandial glucagon, and supports better overall glucose regulation, with potential for prediabetes reversal or normoglycemia in a large proportion of participants.
Favorable Cardiometabolic and Body Composition Improvements
Reductions in waist circumference (up to –13.4 cm), systolic blood pressure (–6.7 to –10.9 mmHg), and inflammatory markers (e.g., high-sensitivity C-reactive protein).
Improvements in lipid profiles, liver fat, and other metabolic parameters beyond what weight loss alone explains in some analyses.
Supports better physical function scores (e.g., IWQOL-Lite-CT and SF-36) and overall quality of life related to mobility and daily activities.
Synergistic Advantages Over Monotherapy
Dual targeting of complementary hunger/satiety pathways (GLP-1 for central and gut effects + amylin for brainstem reinforcement) creates broader appetite regulation and potentially delays or reduces weight loss plateaus.
Additive effects on energy balance, gastric motility, and metabolic signaling lead to greater total weight reduction and metabolic benefits than semaglutide or cagrilintide used individually.
Maintains a profile consistent with the GLP-1 class while delivering meaningful incremental efficacy through amylin co-activation.
